Crescent Biopharma
(NASDAQ) CBIO
Crescent Biopharma Financials at a Glance
Market Cap
$500.71M
Revenue (TTM)
$41.41M
Net Income (TTM)
$141.14M
EPS (TTM)
$-15.35
P/E Ratio
-1.18
Dividend
$0.00
Beta (Volatility)
0.82 (Low)
Dividend
$0.00
Beta (Volatility)
0.82 (Low)
Price
$18.13
Volume
154,657.787
Open
$18.86
Price
$18.13
Volume
154,657.787
Open
$18.86
Previous Close
$18.17
Daily Range
$18.10 - $19.16
52-Week Range
$8.72 - $28.77
Dividend
$0.00
Beta (Volatility)
0.82 (Low)
Price
$18.13
Volume
154,657.787
Open
$18.86
Previous Close
$18.17
Daily Range
$18.10 - $19.16
52-Week Range
$8.72 - $28.77
CBIO News
CBIO: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Crescent Biopharma
Industry
Biotechnology
Sector
Health CareEmployees
44
CEO
Joshua T. Brumm
Website
www.crescentbiopharma.comHeadquarters
Waltham, MA 02451, US
CBIO Financials
Key Financial Metrics (TTM)
Gross Margin
96%
Operating Margin
-3%
Net Income Margin
-3%
Return on Equity
-135%
Return on Capital
-69%
Return on Assets
-59%
Earnings Yield
-84.75%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$500.71M
Shares Outstanding
27.56M
Volume
154.66K
Short Interest
0.00%
Avg. Volume
210.49K
Financials (TTM)
Gross Profit
$10.76M
Operating Income
$152.63M
EBITDA
$149.67M
Operating Cash Flow
$71.53M
Capital Expenditure
$919.00K
Free Cash Flow
$72.45M
Cash & ST Invst.
$213.19M
Total Debt
$1.64M
Crescent Biopharma Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$10.84M
N/A
Gross Profit
$10.79M
+39799.4%
Gross Margin
99.50%
N/A
Market Cap
$500.71M
N/A
Market Cap/Employee
$12.21M
N/A
Employees
41
N/A
Net Income
$92.40M
-1179.2%
EBITDA
$99.89M
-487.1%
Quarterly Fundamentals
Net Cash
$211.55M
+1885.7%
Accounts Receivable
$18.00M
+13079.1%
Inventory
$0.00
N/A
Long Term Debt
$1.21M
-96.8%
Short Term Debt
$435.00K
+550.8%
Return on Assets
-58.74%
N/A
Return on Invested Capital
-68.95%
N/A
Free Cash Flow
$22.13M
+697.9%
Operating Cash Flow
$22.21M
+700.2%